The BEXXAR therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is an anti-neoplastic radioimmunotherapeutic monoclonal antibody-based regimen composed of the monoclonal antibody, Tositumomab, and the radiolabeled monoclonal antibody, Iodine I 131 Tositumomab.
The BEXXAR therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma, including patients with Rituximab-refractory non-Hodgkin’s lymphoma. Determination of the effectiveness of the BEXXAR therapeutic regimen is based on overall response rates in patients whose disease is refractory to chemotherapy alone or to chemotherapy and Rituximab. The effects of the BEXXAR therapeutic regimen on survival are not known.
The BEXXAR therapeutic regimen is not indicated for the initial treatment of patients with CD20 positive non-Hodgkin’s lymphoma. (See ADVERSE REACTIONS, Immunogenicity.)
The BEXXAR therapeutic regimen is intended as a single course of treatment. The safety of multiple courses of the BEXXAR therapeutic regimen, or combination of this regimen with other forms of irradiation or chemotherapy, has not been evaluated.
Media Articles Related to Bexxar (Tositumomab / Iodine I 131 Tositumomab)
Not Clear: Best Use of Rituximab in Follicular Lymphoma
Source: Medscape Hematology-Oncology Headlines [2014.04.16]
Watching and waiting is the accepted practice for managing patients with asymptomatic, advanced-stage nonbulky follicular lymphoma. But another strategy is being championed.
Medscape Medical News
Lymphoma development and progression may be promoted by inhibition of CDK4
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.03.24]
Anticancer agents that target a cell-cycle regulatory protein to inhibit tumor growth might actually promote the development and progression of certain B-cell lymphomas, according to a new study led...
Novel Drug Shows Promise in T-Cell Lymphoma
Source: MedPage Today Dermatology [2014.03.24]
DENVER (MedPage Today) -- An investigational drug, resiquimod, successfully healed cutaneous T-cell lymphoma lesions in a small peer-supported trial, researchers reported here.
Early PET negative patients with stage I/II Hodgkin lymphoma show Increased risk of early relapse when radiotherapy is omitted
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.03.22]
Interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial published in the Journal of Clinical Oncology indicates an increased risk of early relapse when omitting radiotherapy in early PET...
New drug offers potential for chemo-free treatment for leukemia/lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.03.21]
Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side...
Published Studies Related to Bexxar (Tositumomab / Iodine I 131 Tositumomab)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. [2005.10.20]
PURPOSE: This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refractory low-grade, follicular, or transformed low-grade non-Hodgkin's lymphoma (NHL) that resulted in the regulatory approval of the iodine-131 tositumomab by the US Food and Drug Administration... CONCLUSION: The tositumomab and iodine-131 tositumomab therapeutic regimen produces high response rates in patients with relapsed or refractory low-grade, follicular, and transformed low-grade NHL, with a sizable subgroup of patients achieving long-term durable responses.
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. [2011.06]
The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma... CONCLUSION: Optimal patient benefit might be obtained in indolent lymphoma when administering radioimmunotherapy up-front in combination with chemotherapy and rituximab treatment. However, these results show that radioimmunotherapy alone achieved long-lasting remissions in 6 of 12 (50%) indolent lymphoma patients in relapse after 1 or multiple chemotherapies.
Tositumomab and iodine I 131 tositumomab (Bexaar). [2011.04]
Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen..
Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab. [2011.04]
Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy.Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [(90)Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations.
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. [2010.12]
This study aimed at identifying clinical factors for predicting hematologic toxicity after radioimmunotherapy with (90)Y-ibritumomab tiuxetan or (131)I-tositumomab in clinical practice... CONCLUSION: The elapsed time since the last chemotherapy can be used to predict hematologic toxicity and customize the current dosing method in radioimmunotherapy.
Clinical Trials Related to Bexxar (Tositumomab / Iodine I 131 Tositumomab)
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma [Recruiting]
The purpose of this study is to find the highest safe dose of Iodine-131 Tositumomab
(Bexxar®) that can be given to patients who have relapsed/refractory Hodgkin's lymphoma,
what side effects these patients get when they take Bexxar® and if Bexxar® is effective in
treating relapsed/refractory Hodgkin's lymphoma. Bexxar® works by delivering doses of
radiation to cancer cells.
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma [Recruiting]
This study is for patients with newly diagnosed or relapsed multiple myeloma. The main
purpose of this study is to see how their disease responds to consolidation treatment
(treatment aimed at further decreasing cancer cells) with a radioactive antibody (protein)
called iodine I 131 tositumomab (known by the tradename Bexxar®) and also to look at the
side effects which occur with this type of treatment. The investigators will also be
looking at how long disease responds to treatment, if it responds at all, and how long
patients who have had this treatment survive.
Bexxar is a monoclonal antibody (protein) to which radioactive iodine 131 is attached. The
monoclonal antibody in Bexxar (tositumomab), targets a protein called CD20 found on the
surface of a variety of B-cells, including lymphoma cells, and some myeloma cells. The
antibody is given as an infusion and finds its way to these cells. The radioactive iodine
attached to the antibody delivers radiation directly to these cells which works to harm or
kill the cancer cells. Approximately 20-25% of patients with multiple myeloma have this
protein on the surface of their tumor cells. In addition, this protein was found on the
surface of myeloma stem cells. While myeloma stem cells represent a minority of all myeloma
cells (less than 5%), these cells are resistant to chemotherapy and are believed to be
responsible for a recurrence of the disease after chemotherapy. In this study, Bexxar will
be used after patients complete a course of chemotherapy and have residual myeloma cells
left in their body. The Investigators are hoping that the treatment with Bexxar will
decrease and possibly eliminate residual myeloma cells resistant to chemotherapy.
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission [Recruiting]
This phase II trial studies how well tositumomab and iodine I 131 tositumomab works in
treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma
(SLL) in first remission. Monoclonal antibodies, such as tositumomab and iodine I 131
tositumomab, can block cancer growth in different ways. Some block the ability of cancer to
grow and spread. Others find cancer cells and help kill them or carry cancer cancer-killing
substances to them
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant [Recruiting]
Patients with B-cell lymphoma who relapse after autologous transplant tend to have a poor
prognosis. Currently, there is no standard treatment for such patients. Bexxar is a
radioactive antibody therapy that has shown a 60-80% response rate in non-transplanted
patients with relapsed B-cell lymphoma. This study will test the safety and efficacy of
Bexxar in the treatment of patients whose B-cell lymphoma has relapsed after an autologous
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find
cancer cells and carry cancer-killing substances to them without harming normal cells. Drugs
used in chemotherapy, such as fludarabine phosphate, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. A
peripheral stem cell transplant may be able to replace blood-forming cells that were
destroyed by chemotherapy and radiation therapy. Giving iodine I 131 tositumomab together
with fludarabine phosphate followed by autologous stem cell transplant may be an effective
treatment for non-Hodgkin's lymphoma.
PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when
given together with iodine I 131 tositumomab in treating older patients who are undergoing
an autologous or syngeneic stem cell transplant for relapsed or refractory B-cell